Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | RETRACTABLE TECHNOLOGIES INC - 8-K, Current Report | 1 | SEC Filings | ||
RETRACTABLE TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
06.06. | Retractable Technologies ernennt nach Fusion neuen Wirtschaftsprüfer | 1 | Investing.com Deutsch | ||
06.06. | RETRACTABLE TECHNOLOGIES INC - 8-K, Current Report | - | SEC Filings | ||
15.05. | RETRACTABLE TECHNOLOGIES INC - 8-K, Current Report | 4 | SEC Filings | ||
15.05. | RETRACTABLE TECHNOLOGIES INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
11.04. | RETRACTABLE TECHNOLOGIES INC - 8-K, Current Report | 2 | SEC Filings | ||
11.04. | Retractable Technologies cuts workforce to reduce reliance on China amid trade war | 1 | MassDevice | ||
10.04. | Retractable Technologies reduces workforce by about 7% | 1 | Seeking Alpha | ||
31.03. | Retractable Technologies declares $1.00 dividend | 3 | Seeking Alpha | ||
28.03. | Retractable Technologies reports FY results | 1 | Seeking Alpha | ||
28.03. | RETRACTABLE TECHNOLOGIES INC - 8-K, Current Report | 1 | SEC Filings | ||
28.03. | RETRACTABLE TECHNOLOGIES INC - 10-K, Annual Report | 2 | SEC Filings | ||
14.01. | RETRACTABLE TECHNOLOGIES INC - 8-K, Current Report | - | SEC Filings | ||
02.01. | Retractable Technologies declares $1.00 dividend | 7 | Seeking Alpha | ||
14.11.24 | Retractable Technologies, Inc. Results for the Periods Ended September 30, 2024 | 131 | Business Wire | LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $10.3 million for the third quarter of 2024 and an operating loss of $5.1 million... ► Artikel lesen | |
14.08.24 | Retractable Technologies, Inc. Results for the Periods Ended June 30, 2024 | 130 | Business Wire | LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $6.0 million for the second quarter of 2024 and an operating loss of $5.8 million... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ROKU | 74,75 | +0,13 % | Should You Buy Roku Stock After Its Partnership With Amazon? | ||
BICO GROUP | 3,200 | -0,06 % | Bico Group Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
SERNOVA BIOTHERAPEUTICS | 0,094 | -3,09 % | Sernova Biotherapeutics, Inc.: Sernova Appoints Jonathan Rigby as Interim Chair | LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,745 | +3,33 % | Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline | ||
PING AN HEALTHCARE | 0,937 | -1,18 % | PA GOODDOCTOR (01833): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2025 | ||
CO-DIAGNOSTICS | 0,240 | +1,69 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
CYTOSORBENTS | 1,092 | +1,68 % | Cytosorbents Corp: CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb-ATR | PRINCETON, N.J., June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
VERU | 0,511 | +2,18 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China | Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest... ► Artikel lesen | |
VOLITIONRX | 0,835 | 0,00 % | VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., May 15, 2025 /PRNewswire/... ► Artikel lesen | |
EKSO BIONICS | 3,280 | 0,00 % | XFRA 23E0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEKSO BIONICS. NEW... ► Artikel lesen | |
IMUNON | 0,685 | +0,74 % | Imunon, Inc.: IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 | ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 47,060 | +0,34 % | Neue 5,68% Aktienanleihe auf Siemens Healthineers | Düsseldorf (www.anleihencheck.de) - Die HSBC Trinkaus & Burkhardt AG, Düsseldorf, bietet ab dem 24. Juni 2025 eine neue Aktienanleihe (ISIN DE000HT69A65/ WKN HT69A6) auf die Aktie der Siemens Healthineers... ► Artikel lesen | |
FRESENIUS | 42,700 | +0,26 % | Aktienmarkt: Fresenius SE & Co. KGaA-Aktie kann sich nicht behaupten (42,16 €) | Der Anteilsschein von Fresenius SE & Co. KGaA notiert am Mittwoch leichter. Die Aktie kostete zuletzt 42,16 Euro. Für Inhaber von Fresenius+Co KgaA ist der heutige Handelstag bisher nicht sonderlich... ► Artikel lesen | |
GERRESHEIMER | 47,880 | -0,42 % | Gerresheimer-Aktie heute gut behauptet: Aktienwert steigt (47,28 €) | Am deutschen Aktienmarkt notiert der Anteilsschein von Gerresheimer gegenwärtig etwas fester. Die Aktie kostete zuletzt 47,28 Euro. Die Aktie von Gerresheimer verzeichnet derzeit einen Preisanstieg... ► Artikel lesen |